Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | HMGCR | P04035 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17620221 | 1.00 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL17620173 | 1.00 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL17620209 | 1.00 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL3663518 | 1.00 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL1728378 | 1.00 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL3272584 | 1.00 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL6022376 | 1.00 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL3663517 | 1.00 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL14103187 | 1.00 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL2493929 | 0.99 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111615400-B | Accurate glycoconjugates as therapeutic tools | 科纳克斯资本 | 2025-05-02 | — | — | CN | disclosed |
| US-20240216491-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2024-07-04 | — | — | US | disclosed |
| US-11925680-B2 | Neoglycoconjugates as vaccines and therapeutic tools | KORANEX CAPITAL (CA) | 2024-03-12 | — | — | US | disclosed |
| EP-4277914-A1 | PROCESS FOR THE SYNTHESIS OF REACTIVE CARBOHYDRATES INCLUDING ANTIGEN PRECURSORS FOR CONJUGATION WITH A CARRIER MATERIAL | Koranex Capital (CA) | 2023-11-22 | — | — | EP | disclosed |
| EP-4034159-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | Koranex Capital (CA) | 2022-08-03 | — | — | EP | disclosed |
| WO-2022150924-A1 | PROCESS FOR THE SYNTHESIS OF REACTIVE CARBOHYDRATES INCLUDING ANTIGEN PRECURSORS FOR CONJUGATION WITH A CARRIER MATERIAL | KORANEX CAPITAL (CA) | 2022-07-21 | — | — | WO | disclosed |
| US-10973910-B1 | Neoglycoconjugates as vaccines and therapeutic tools | KORANEX CAPITAL (CA) | 2021-04-13 | — | — | US | disclosed |
| WO-2021056098-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2021-04-01 | — | — | WO | disclosed |
| US-20210085770-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2021-03-25 | — | — | US | disclosed |
| US-20210085781-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2021-03-25 | — | — | US | disclosed |
| EP-1609798-B1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-1609798-A9 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7998975-B2 | Sodium dependent glucose transporter inhibition; hyperglycemia associated diseases; 3-glucopyranosyloxy- 1H-indazole and 1H-pyrazolo[3,4-b]pyridine derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7566699-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20080188426-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-7375113-B2 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20070191289-A1 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1724278-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1609798-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085770-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | USP2 86/4885POLB 3714/4885MEN1 3455/4885 |
| US-20070191289-A1 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | SLC5A1, SLC5A2, GPR119 | USP2 3397/4885POLB 4672/4885MEN1 2923/4885 |
| US-20080188426-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | SLC5A1, SLC5A2, SLC2A1 | USP2 3329/4885POLB 4661/4885MEN1 3082/4885 |
| US-20240216491-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | USP2 86/4885POLB 3714/4885MEN1 3455/4885 |
| US-20210085781-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | USP2 86/4885POLB 3714/4885MEN1 3455/4885 |
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | USP2 3761/4885POLB 4666/4885MEN1 4045/4885 |
| US-11925680-B2 | Neoglycoconjugates as vaccines and therapeutic tools | GNE, B3GNT2, KRTCAP2 | USP2 86/4885POLB 3714/4885MEN1 3455/4885 |
| US-10973910-B1 | Neoglycoconjugates as vaccines and therapeutic tools | GNE, B3GNT2, KRTCAP2 | USP2 86/4885POLB 3714/4885MEN1 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.